// App-Quantinova.ai

: Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Researchers

Presenter

  • Yasutaka Ueda

Principal Investigators

  • Hiroyuki Takamori

  • Jun-Ho Jang

  • Chezi Ganzel

  • Saskia Langemeijer

  • Makiko Osato

  • Petra Muus

  • Jong-Wook Lee

  • Jun-Ichi Nishimura

  • Yuzuru Kanakura

Medical Centers

  • Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan

  • Japan PNH Study Group, Tokyo, Japan

  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

  • Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

  • Department of Oncology, King's College Hospital, London, United Kingdom

  • The Catholic University of Korea, Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, Seoul, Korea, Republic of (South)

Locations

  • Japan

  • Republic of South Korea

  • Israel

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved